Health Plans Embrace Biosimilars to Reduce Costs and Improve Patient Access | AMCP Nexus 2024 How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and ...
It's not the multimillion dollar prices, says Kevin Niehoff, Pharm.D., of IPD Analytics. The pool of sickle cell disease patients who are prime candidates for sickle cell disease gene therapy was ...
The role of AI is ever-evolving, especially for healthcare decision makers, according to Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora. AI leads to an increase in ...
Steven Levine, MD: Carrie, can you talk about what’s involved in procuring intranasal esketamine [Spravato], the various routes, whether that’s buy-and-bill or specialty pharmacy, and any of the ...
Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.
Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.